Proprietary due diligence that uncovers hidden risks in genomic data companies – before you sign. We combine data science, legal expertise, and financial forensics so you never inherit a surprise.
Traditional due diligence was not designed for the complexity of genomic data companies. Our services address every dimension of risk before you commit capital.
3-day rapid assessment covering legal, technical, financial & operational risks. Identify deal-breakers early.
10-day comprehensive analysis with integration risk modeling. Full-spectrum intelligence before you sign.
A la carte audits — Legal, Technical/IP, Financial, or Operational. Choose only what you need.
Bronze, Silver, and Gold tiers for VCs and PE firms managing multiple deals with volume pricing.
Bundled RFA + DDD packages for high-volume acquirers. Available by request for maximum value.
Our team has extensive experience in genomic due diligence, having conducted in-depth analyses across a range of companies in the multi-omics, sequencing, and data integration sectors. Contact us for a list of recent engagements.
IP ownership, FDA/EMA regulatory status, HIPAA/GDPR posture, and freedom-to-operate analysis before you commit.
Reproducibility scores, pipeline architecture, API stability, and data provenance tracking across the genomic stack.
Forensic accounting ratios, burn rate modeling, team turnover signals, and integration cost quantification.
Book a 15-minute discovery call using the calendar, or email us directly. We'll walk you through how our process works and scope the right engagement for your deal timeline.
Not sure which service fits? Start with a free demo assessment — we'll run a sample risk profile on a target of your choice so you can evaluate our depth before committing.
✉ hello@valeborne.com